Associated Papers
Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival.
Dhotare PS et al.
Bmc Cancer, 2025
40597801 (PubMed )
Supplement: 12885_2025_14455_MOESM1_ESM.zip › Supplementary_tables.pdf
Mutation patterns in colorectal cancer and their relationship with prognosis.
Su Z et al.
Heliyon, 2024
39263143 (PubMed )
Supplement: mmc1.xlsx › Tabelle1
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board.
Tarawneh TS et al.
Cancers, 2022
36139590 (PubMed )
Supplement: cancers-14-04430-s001.zip › Tarawneh_et_al_Supplementary_Table_S5.xlsx › Alterations
A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer.
Pfohl U et al.
Cancers, 2022
35805024 (PubMed )
Supplement: cancers-14-03252-s001.zip › Supplementary_Files › Table_S2.xlsx › PDO-models
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.
Gutiontov SI et al.
Scientific Reports, 2021
34625620 (PubMed )
Supplement: 41598_2021_99524_MOESM2_ESM.xlsx › Mutations
Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer.
Wagner S et al.
Cancers, 2021
34572946 (PubMed )
Supplement: cancers-13-04717-s001.zip › cancers-1355846-supplementary.xlsx › Table_S3_SNVs
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
Lowder CY et al.
Surgical Oncology, 2020
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Aggarwal C et al.
Jama Oncology, 2019
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
30709382 (PubMed )
Supplement: 12885_2019_5313_MOESM2_ESM.xlsx › supplementary_2_filtered
Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine.
Hou H et al.
Oncotarget, 2017
29285234 (PubMed )
Supplement: oncotarget-08-105072-s002.xlsx › Data
Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.
Ding L et al.
The Journal of Clinical Investigation, 2009
Novel mutations in Smad proteins that inhibit signaling by the transforming growth factor beta in mammalian cells.
Prokova V et al.
Biochemistry, 2007
Regulation of large-scale chromatin unfolding by Smad4.
Yan J et al.
Biochemical and Biophysical Research Communications, 2004
Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors.
Iacobuzio-Donahue CA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004
Formation of a stable heterodimer between Smad2 and Smad4.
Wu JW et al.
The Journal of Biological Chemistry, 2001
TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads.
Hata A et al.
Molecular Medicine Today, 1998
Select a paper to view details